A novel and objective method of evaluation of the pain component/paresthesia coverage using comparative multiparametric tactile interface software and database analysis

Background/objective: One of the major challenges of neuro-stimulation is actually to address the back pain component in patients suffering from refractory chronic back and leg pain. To be able to evaluate and compare objectively patient outcomes, depending on therapeutic strategies, it appears essential to develop a rational and quantitative approach to pain assessment and neuro-stimulation outcomes for those who undergo neurostimulation implantation.

Materials/methods: Our neuroinformatics laboratory (N3Lab) located in Poitiers University Hospital, Department of Neurosurgery, enabled us to develop the Neuro-Mapping Tools software (N3MT) (Inter Deposit Digital Number: IDDN FR 001-1600002-000-R-P-2013-000-31230; Patent Applications n°PCT/EP2014/067231, n°PCT/FR 14/000 186 and n°PCT/FR 14/000 187). This tool consists of touch screen mapping, allowing the patient and/or the physician to interact by means of a tablet computer to delineate painful zones and paraesthesia coverage in the thoracolumbar region and legs.

Results: The software is used in more than 190 patients since 2012, leading us to describe new measurement parameters, divided into two categories: 1) Technical parameters, evaluating the implanted device itself, 2) Clinical parameters, evaluating patient response to the therapy.

Conclusions: The software is an original software designed to objectively and quantitatively characterize reduction of a painful area in a given individual, in terms of intensity, surface and pain typology, in response to a treatment strategy or implantation of an analgesic device. The software could help to guide tomorrow’s treatment options by transforming personal convictions into a more robust scientific rationale based on data collection and data mining techniques.

doi:10.1016/j.jns.2015.08.309

Multicolumn spinal cord stimulation surgical lead implantation using an optic transligamentar minimally invasive technique

Background: A new generation of neurostimulation surgical leads is used to increase the success of spinal cord stimulation (SCS) in difficult-to-treat indications such as Failed Back Surgery Syndrome (FBSS). This makes the implant procedure more invasive, which is likely to be a determinant factor in clinical and functional outcomes. Minimal access spinal technologies (MAST) have been previously used for surgical lead implantation. However, only a unilateral approach was described, causing some difficulties for median lead placement and not always preventing laminectomy. A recent MAST technique can be used to implant SCS leads without these limitations, which seems to be key in the positive outcomes experienced. The objective is to describe the original MAST technique used in the pilot study.

Methods: Twenty-four consecutive patients were implanted with a multicolumn spinal cord lead for refractory chronic back and leg pain using the optic transligamentar MAST technique described extensively. Clinical outcomes, functional ability and adverse events (AEs), were recorded for up to 12 months after surgery.

Results: The MAST technique allowed median lead placement, facilitated visualization of the spine and permitted transligamentar insertion that minimized scarring and muscle damage, intraoperative blood loss and postoperative functional complications. Back pain decreased significantly at all follow-up, while functional status improved significantly at 1 year. No technique-related AEs were reported.

Conclusions: Use of MAST approach could be useful in safe implantation of multicolumn surgical leads and confer major advantages in difficult-to-treat refractory lower back pain conditions such as FBSS.

doi:10.1016/j.jns.2015.08.310
235  
WFN15-0622  
Pain 2  
Time course of therapeutic response to mirror therapy for phantom limb pain  
S.C. Griffina, S.E.A.N. Curranb, P.F. Pasquinab, J.W. Tsao  
a, Physical Medicine & Rehabilitation, Walter Reed National Military Medical Center, Bethesda, MD; b, Physical Medicine & Rehabilitation, Uniformed Services University of the Health Sciences, Bethesda, USA; c, Neurology, University of TN Health Science Center, Memphis, USA  

Background: Mirror therapy is an effective treatment for most amputees experiencing phantom limb pain (PLP), yet optimal treatment parameters, including the duration of treatment, have not been established.  
Objective: We sought to delineate the time course of mirror therapy treatment effects patients with major limb loss.  
Methods: We conducted a post hoc analysis of two independent cohorts of persons with lower extremity amputation (N = 29) enrolled in IRB approved research at Walter Reed National Military Medical Center, Bethesda, MD who received mirror therapy daily for 4 weeks. PLP was assessed on each treatment day using the McGill Pain Questionnaire – Short Form (SF-MPQ), measuring 15 pain descriptors on a 0–100 visual analog scale (VAS). Paired t-tests comparing pain at weekly time points to baseline pain were used to detect substantial reductions in pain.  
Results: Paired-sample t-tests showed significant declines in VAS and SF-MPQ scores after the first week (p < .003 and p < .001, respectively), which persisted after two weeks (p < .007 and p < .001) and four weeks (p < .003 and p < .001). Amputees with VAS pain levels ≤60/100 (N = 19) showed a significant decline in pain after only one week, while those with pain levels >61/100 (N = 10) required at least two weeks of treatment.  
Conclusions: These results indicate that the benefits of mirror therapy can be seen within 4 weeks. Since some patients do not benefit from mirror therapy, a trial lasting 1–2 weeks, stratified based on baseline pain, should be sufficient to determine if there will be a therapeutic response at 4 weeks.  

doi:10.1016/j.jns.2015.08.312

236  
WFN15-0684  
Pain 2  
Use of ultra-sound guided transversus abdominis plane block for effective postoperative analgesia among patients undergoing gynecologic surgery  
T. Hussaina, A. Anwar Mira, bDepartment of Medicine and Allied Specialties, Holy Family Hospital Rawalpindi Medical College, Rawalpindi, Pakistan; cDepartment of Medicine and Allied Specialties, Shifa Hospital Shifa College of Medicine, Islamabad, Pakistan  

Introduction: Ultrasound guided total abdominal block (US-TAP) is a new and effective technique for decreasing post operative pain after abdominal surgeries. The objective of this study was to evaluate the use of ultrasound guided transversus abdominis plane block for effective postoperative analgesia in patients undergoing gynecologic surgery via a transverse lower abdominal skin incision.  
Methods: This randomized control trial study was conducted at Holy Family Hospital, Rawalpindi for a period of 6 months from July 2014 to Dec 2014. 200 female patients undergoing gynecologic surgery via transverse lower abdominal skin incision were enrolled in the study. Patients were divided into two groups by using consecutive non-probability sampling; both received ultra-sound guided transversus abdominis plane block with either bupivacaine (Group A) or saline (Group B). Comparison of early mean post operative pain relief was assessed with ultra-sound guided transversus abdominis plane block with or without bupivacaine. SPSS version 17.0 was used to analyze the data.  
Results: The mean age of patients was 41 years (range 17–71). There were 100 patients in each group. The two groups were comparable with respect to baseline features. The US-TAP block significantly reduced pain intensity as compared to standard care in the PACU at 4 h (5.2 ± 3.1 vs. 8.4 ± 1.3, p = 0.003). There was insignificant difference between the visual assessment score of pain at 8 h between the two study groups (3.6 ± 2.3 vs. 2.3 ± 2.4, p = 0.4).  
Conclusion: Ultra-sound guided transversus abdominis plane block (TAP) is an effective modality for reducing post operative pain after gynecologic surgery via a transverse lower abdominal skin incision.

doi:10.1016/j.jns.2015.08.311

238  
WFN15-1381  
Pain 2  
Efficacy of flupirtine modified release in chronic tension-type headache with without pericranial tenderness  
M.A. Ueberralta, G.H.H. Mueller-Schwefta, bIFNAP, Institute for Neurological Sciences, Nuernberg, Germany; cDGS, Interdisciplinary Center for Pain and Palliative Care Medicine, Goepplingen, Germany  

Background: Flupirtine is an old effective analgesic drug for the treatment of headaches and muscle pain. There have been limited studies evaluating its efficacy in chronic tension-type headache (CTTH).  
Objective: The aim of this study was to provide evidence for the efficacy of flupirtine MR in CTTH.  
Methods: This was a 6 months randomized double-blind placebo controlled trial at two university hospitals. Patients with CTTH with or without pericranial tenderness were randomized into two groups: Group A received 400 mg of flupirtine MR daily and group B 200 mg of flupirtine MR daily.  
Results: Of the 186 patients included in the study, 101 were included in the final analysis. The efficacy of the treatment was evaluated using the headache frequency and intensity. The headache frequency was significantly lower in the flupirtine group than in the placebo group (p = 0.001). The headache intensity was not significantly different between the two groups (p = 0.2).  
Conclusion: Flupirtine modified release is effective in the treatment of chronic tension-type headache with or without pericranial tenderness.

doi:10.1016/j.jns.2015.08.313
**Background:** Current HIS-classification differentiates between chronic tension-type headaches with (cTTH+) and without (cTTH−) pericranial tenderness, however pharmacological treatment strategies don’t.

**Objective:** To evaluate efficacy and tolerability of flupirtine modified release (FMR) — a muscle tone normalizing analgesic.

**Patients and Methods:** Patients with cTTH+/cTTH− received a 7 day open-label treatment with FMR (400 mg OD in the evening) during this non-interventional study. Pain intensity (NRS11), number of hours with pain, and pain-related restrictions in daily life activities were documented at baseline (prior FMR), and daily after treatment onset using standardized pain diaries. Adverse events (AE) were reported during the course of the study.

**Results:** Overall, 89 patients with cTTH (79 with/10 without PT) participated. 75.3% were female; mean age was 53.8 ± 14.1 years and 51.7% suffered for more than 6 months. With FMR, average number of daily TTH hours dropped for cTTH+/cTTH− from 11.3 ± 6.3/7.6 ± 3.4 h at baseline to 4.8 ± 3.9 (p < 0.001)/6.4 ± 2.8 (p = ns) at end-of-study. In parallel, average pain intensity dropped from 6.5 ± 1.9/5.3 ± 1.2 (95%-CI: 4.9–5.5) to 2.7 ± 1.7 (p < 0.001)/4.4 ± 1.3 (p = ns) NRS11, and average daily life restrictions improved from 5.8 ± 1.9/4.3 ± 1.7 to 2.3 ± 1.6 (p < 0.001)/3.4 ± 1.0 (p = ns) NRS11. No treatment emergent adverse events were reported.

**Conclusions:** Differential therapeutic benefits seen with FMR in patients suffering from cTTH+/− relate to its unique pharmacological (muscle tone normalizing) properties. The results of this naturalistic study focusing on patient-reported outcomes support taxonomic strategies to differentiate between cTTH with/without PT, and raises questions about current uniform recommendations for cTTH treatment.

**doi:** 10.1016/j.jns.2015.08.314

---

**Pain 2**

**Paragangliomas-case**

S. Gomes, Neurology, b. Portuguesa, Sao Paulo, Brazil

One uncommon case of paragangliomas arising from the vagus nerve is described. The patient underwent surgery for suspected carotid body tumour, and computed tomography scan and digital angiography allowed a correct pre-operative diagnosis to be made. This case confirms the prevalence of vagal paragangliomas in female sex and middle age, and the possibility of multiple similar tumours in the same patient. Histological benign features, absence of neurological symptoms, lack of local invasion or intracranial extension confirm the frequent benign behaviour of these neoplasms. Lack of catecholamine secretion confirms the low incidence of functioning tumours. Contrast computed tomography and digital angiography still remain the gold standard reliable instruments for diagnosis despite the success of magnetic resonance imaging, magnetic resonance angiography and octreotide scintigraphy to detect head and neck paragangliomas. A transcervical approach, without mandibulotomy, is suitable for large tumours but complete removal, with sparing of involved segments of the vagus nerve, is rarely possible. Post-operative neurological morbidity is still an unsolved issue and, therefore, rehabilitation of deglutition and phonation is an integral part of management.

**doi:** 10.1016/j.jns.2015.08.315